{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:44Z","timestamp":1793400704681,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jacc.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T13:59:52Z","timestamp":1621864792000},"page":"2693-2716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents"],"prefix":"10.1016","volume":"77","author":[{"given":"Vijay U.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul R.","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"O\u2019Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Raghavendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.04.009_bib1","article-title":"Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment","author":"Saleh","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2021.04.009_bib2","first-page":"87","article-title":"Left ventricular dysfunction in cancer treatment: is it relevant?","volume":"6","author":"Kenigsberg","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.04.009_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019865704","article-title":"EXPRESS: pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors","author":"El-Dabh","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jacc.2021.04.009_bib5","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.04.009_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib7","first-page":"1023","article-title":"Frequency of transition from stage A to stage B heart failure after initiating potentially cardiotoxic chemotherapy","volume":"6","author":"Jones","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.04.009_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2021.04.009_bib9","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.04.009_bib10","first-page":"135","article-title":"Incidental coronary artery calcification in cancer imaging","volume":"1","author":"Cuddy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jacc.2021.04.009_bib11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.04.009_bib12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jacc.2021.04.009_bib13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-94-4-430","article-title":"Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography","volume":"94","author":"Gottdiener","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.04.009_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12968-017-0348-4","article-title":"Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance","volume":"19","author":"Huang","year":"2017","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2021.04.009_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.04.009_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000495147","article-title":"False positive cardiotoxicity events in cancer-related clinical trials: risks related to imperfect noninvasive parameters","volume":"63","author":"Ewer","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jacc.2021.04.009_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib18","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group","volume":"18","author":"Lang","year":"2005","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.04.009_bib19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.echo.2008.09.009","article-title":"American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography","volume":"21","author":"Mulvagh","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.04.009_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/ejechocard\/jep005","article-title":"Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography","volume":"10","author":"Senior","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2021.04.009_bib21","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/eurheartj\/ehn484","article-title":"Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging","volume":"30","author":"Jenkins","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.04.009_bib23","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.04.009_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/CIRCIMAGING.109.862334","article-title":"Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring","volume":"2","author":"Stanton","year":"2009","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2021.04.009_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jacc.2009.04.061","article-title":"Global 2-dimensional strain as a new prognosticator in patients with heart failure","volume":"54","author":"Cho","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib27","first-page":"677","article-title":"Strain imaging in cardio-oncology","volume":"2","author":"Liu","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jacc.2021.04.009_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/euhj.1997.0787","article-title":"The clinical role of magnetic resonance in cardiovascular disease","volume":"19","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.04.009_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1161\/01.CIR.82.1.154","article-title":"Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography","volume":"82","author":"Cranney","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.009_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10976640009148691","article-title":"Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance","volume":"2","author":"Bellenger","year":"2000","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2021.04.009_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2018.10.023","article-title":"CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping","volume":"275","author":"Haslbauer","year":"2019","journal-title":"Int J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2021.04.009_bib33","doi-asserted-by":"crossref","first-page":"P273","DOI":"10.1186\/1532-429X-16-S1-P273","article-title":"Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab","volume":"16","author":"Thavendiranathan","year":"2014","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2021.04.009_bib34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcmg.2020.09.039","article-title":"Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography","volume":"14","author":"Houbois","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2021.04.009_bib35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa0900428","article-title":"Early diagnosis of myocardial infarction with sensitive cardiac troponin assays","volume":"361","author":"Reichlin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.04.009_bib36","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.009_bib37","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2021.04.009_bib39","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.04.009_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.seminoncol.2019.11.002","article-title":"Cardio-oncological management of patients","volume":"46","author":"Cardinale","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart\u00a0Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"53","author":"Hunt","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib43","first-page":"24","article-title":"Use of sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jacc.2021.04.009_bib44","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril-valsartan in cancer patients with heart failure","volume":"7","author":"Martin-Garcia","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"Suppl","key":"10.1016\/j.jacc.2021.04.009_bib46","article-title":"The impact of mild left ventricular dysfunction on trastuzumab use and oncologic outcomes in early stage breast cancer therapy","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3747\/co.26.4631","article-title":"An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction","volume":"26","author":"Barron","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jacc.2021.04.009_bib49","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.04.009_bib53","first-page":"1491","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2021.04.009_bib54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12265-019-09924-y","article-title":"Electrophysiology translational considerations in cardio-oncology: QT and beyond","volume":"13","author":"Alomar","year":"2020","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacc.2021.04.009_bib55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-019-0797-z","article-title":"Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies","volume":"21","author":"Rhea","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jacc.2021.04.009_bib56","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820931808","article-title":"Electrocardiographic changes associated with ibrutinib exposure","volume":"27","author":"Fradley","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.jacc.2021.04.009_bib59","article-title":"Role of sarcoplasmic reticulum calcium in development of secondary calcium rise and early afterdepolarizations in long QT syndrome rabbit model","volume":"10","author":"Chang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.04.009_bib60","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2021.04.009_bib61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jacc.2021.04.009_bib62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00228-016-2120-3","article-title":"High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate","volume":"72","author":"Jamani","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2021.04.009_bib63","first-page":"459","article-title":"Arrhythmogenic anticancer drugs in cardio-oncology","volume":"37","author":"Rhea","year":"2019","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacc.2021.04.009_bib64","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jacc.2018.10.043","volume":"74","author":"Kusumoto","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib65","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3332\/ecancer.2008.130","article-title":"QTc prolongation assessment in anticancer drug development: clinical and methodological issues","volume":"3","author":"Curigliano","year":"2009","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jacc.2021.04.009_bib67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","article-title":"QT prolongation and oncology drug development","volume":"7","author":"Fradley","year":"2015","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.jacc.2021.04.009_bib68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/CIRCRESAHA.116.303975","article-title":"Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels","volume":"116","author":"Ballou","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2021.04.009_bib69","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide","volume":"32","author":"Roboz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11864-019-0657-y","article-title":"QT interval prolongation associated with cytotoxic and targeted cancer therapeutics","volume":"20","author":"Chandrasekhar","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib71","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-Sanchez","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.04.009_bib72","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2021.04.009_bib73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fcvm.2020.00145","article-title":"Innovation in precision cardio-oncology during the coronavirus pandemic and into a post-pandemic world","volume":"7","author":"Brown","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2021.04.009_bib74","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jacc.2021.04.009_bib75","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.009_bib76","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jacc.2021.04.009_bib77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jacc.2021.04.009_bib78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jch.12273","article-title":"Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2014","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacc.2021.04.009_bib79","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2021.04.009_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/clpt.2014.63","article-title":"Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies","volume":"96","author":"Karovic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2021.04.009_bib81","first-page":"372","article-title":"White coat effect in breast cancer patients undergoing chemotherapy","volume":"12","author":"Costa","year":"2003","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.jacc.2021.04.009_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.04.009_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jacc.2021.04.009_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2021.04.009_bib85","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ndt\/gfv410","article-title":"Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib","volume":"31","author":"Lankhorst","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2021.04.009_bib86","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/HYPERTENSIONAHA.111.183368","article-title":"Endothelin 1 activation of endothelin A receptor\/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension","volume":"59","author":"Chen","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2021.04.009_bib87","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ajh.2009.24","article-title":"Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats","volume":"22","author":"Bridges","year":"2009","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2021.04.009_bib88","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2021.04.009_bib89","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2174\/1570161117666190130165810","article-title":"Tyrosine kinase inhibitor-induced hypertension: role of hypertension as a biomarker in cancer treatment","volume":"17","author":"Budolfsen","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacc.2021.04.009_bib90","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2021.04.009_bib91","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","article-title":"Hypertension and VEGF (vascular endothelial growth factor) receptor tyrosine kinase inhibition: effects on renal function","author":"Boursiquot","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2021.04.009_bib92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jacc.2021.04.009_bib93","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacc.2021.04.009_bib94","first-page":"238","article-title":"Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management","volume":"1","author":"Cohen","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jacc.2021.04.009_bib96","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1200\/JCO.2015.61.5948","article-title":"Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer","volume":"34","author":"Ferguson","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib97","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1245\/s10434-012-2631-9","article-title":"Lifestyle risk factors associated with arm swelling among women with breast cancer","volume":"20","author":"Showalter","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib98","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a Scientific Statement from the American Heart Association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2021.04.009_bib99","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib100","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2021.04.009_bib101","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib102","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacc.2021.04.009_bib103","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.2020.9184","article-title":"Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States","volume":"323","author":"Vaduganathan","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.04.009_bib104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Abraham","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacc.2021.04.009_bib105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jacc.2021.04.009_bib106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello","year":"2009","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jacc.2021.04.009_bib107","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0149-2918(97)80046-X","article-title":"Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT)","volume":"19","author":"Toal","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2021.04.009_bib108","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0002-9149(00)01491-0","article-title":"Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension","volume":"87","author":"Kloner","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib109","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0002-9149(00)01199-1","article-title":"Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension","volume":"86","author":"Messerli","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/01.HYP.35.2.621","article-title":"Amlodipine, enalapril, and dependent leg edema in essential hypertension","volume":"35","author":"Pedrinelli","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2021.04.009_bib111","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0002-8703(96)90464-0","article-title":"Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning","volume":"132","author":"Neutel","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.04.009_bib112","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"van Erp","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacc.2021.04.009_bib113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/01.CIR.100.4.346","article-title":"Effect of beta-blockers on free radical-induced cardiac contractile dysfunction","volume":"100","author":"Flesch","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.009_bib114","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the\u00a0CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.009_bib115","first-page":"188","article-title":"Nebivolol (bystolic), a novel beta blocker for hypertension","volume":"34","author":"Hilas","year":"2009","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jacc.2021.04.009_bib116","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.6004\/jnccn.2020.0037","article-title":"NCCN guidelines insights: survivorship, version 2.2020","volume":"18","author":"Denlinger","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jacc.2021.04.009_bib117","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2019.04.010","article-title":"Assessing cardiac safety in oncology drug development","volume":"214","author":"Seltzer","year":"2019","journal-title":"Am Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721012262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721012262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:43:35Z","timestamp":1760017415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721012262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":116,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0735109721012262"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.009","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}